Clinical Trials on Ovarian Malignancy

Total 8933 results

Fred Hutchinson Cancer Center
Swedish Medical Center

Completed

Prevention of Ovarian Cancer in Women Participating in Mammography

Epithelial Ovarian Cancer

United States
King Faisal Specialist Hospital & Research Center

Completed

Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)

Epithelial Ovarian Cancer
Morphotek

Completed

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Epithelial Ovarian Cancer

United States
Medical Research Council

Unknown

Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer

Ovarian Cancer

United Kingdom
EBMT Solid Tumors Working Party

Completed

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Ovarian Cancer

Switzerland, Spain, United Kingdom, Italy, Slovakia, Germany, Belgium, Austria, Czech Republic
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Ovarian Cancer

United States, Canada
NYU Langone Health
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

Ovarian Cancer

United States
Vejle Hospital

Completed

Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type (PaLiDo)

Epithelial Ovarian Cancer

Denmark, Belgium, Sweden, Austria
AGO Study Group

Completed

Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

Epithelial Ovarian Cancer

Germany
Eli Lilly and Company

Completed

Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer

Epithelial Ovarian Cancer

Slovakia
Eunice Kennedy Shriver National Institute of Child...
National Institute on Deafness and Other Communication Disorders (NIDCD)

Terminated

Deep Reading as a Contemplative Practice for Women With Primary Ovarian Insufficiency

Ovarian Insufficiency

United States
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Recruiting

miRNAs in High Grade Serous Ovarian Cancer (MIROC)

High Grade Serous Ovarian Cancer

Italy
Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Recruiting

Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer

Advanced Ovarian Cancer

China
Japanese Gynecologic Oncology Group
Korean Gynecologic Oncology Group

Recruiting

Phase III Trial of Stage I Ovarian Cancer After Surgery

Epithelial Ovarian Cancer

Japan, Korea, Republic of
Tesaro, Inc.

Completed

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer (COHORT-A)

Ovarian Neoplasm

United States
Women's Hospital School Of Medicine Zhejiang University

Active, not recruiting

Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer

Efficacy and Safety

China
Baylor Research Institute

Active, not recruiting

Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer

Epithelial Ovarian Cancer

United States
Morphotek

Terminated

An Open Label Extension Study of the Efficacy of MORAb-003

Epithelial Ovarian Cancer

United States, Germany
PharmaMar

Completed

Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients (NIMES-ROC)

Relapsed Ovarian Cancer

Spain, France, Italy, Belgium, Germany
Universitaire Ziekenhuizen KU Leuven
AstraZeneca

Active, not recruiting

Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer (CLIO)

Ovarian Epithelial Cancer

Belgium
Chang Gung Memorial Hospital
Hoffmann-La Roche; Asian Gynecologic Oncology Group; Taiwanese Gynecolgic Oncology...

Completed

Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer

Epithelial Ovarian Cancer

Taiwan
Immetacyte Ltd

Withdrawn

OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial) (OVSTAR)

Ovarian Cancer Metastatic

United Kingdom
Qianfoshan Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Immune Checkpoint Inhibition

China
Splash Pharmaceuticals, Inc.

Unknown

Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

Ovarian Epithelial Cancer

United States
Assiut University

Unknown

Primary Cyto-reductive Surgery Vs Neo-adjuvant Chemotherapy (NAC) in Epithelial Ovarian Cancer (ovarian cancer)

Advanced Cancer

Egypt
Dr Thumuluru Kavitha Madhuri

Completed

To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC- Initial Feasibility Study (PJEOC)

Epithelial Ovarian Cancer

United Kingdom
Verastem, Inc.

Terminated

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Epithelial Ovarian Cancer

United States
Allife Medical Science and Technology Co., Ltd.

Unknown

Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer

Epithelial Ovarian Cancer
University of California, Davis
National Cancer Institute (NCI)

Completed

Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants

Ovarian Cancer

United States
Yonsei University

Completed

Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy

Advanced-stage Ovarian Cancer

Korea, Republic of
EMD Serono

Withdrawn

Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

Ovarian Cancer
Inge Marie Svane

Completed

TIL Therapy for Metastatic Ovarian Cancer

Metastatic Ovarian Cancer

Denmark
Sunesis Pharmaceuticals

Completed

Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer

Epithelial Ovarian Cancer

United States, Canada
Gynecologic Oncology Associates
University of North Carolina, Chapel Hill

Unknown

Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma

Epithelial Ovarian Carcinoma

United States
Prima BioMed Ltd

Terminated

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (CANVAS)

Epithelial Ovarian Cancer

United States, Australia
SOTIO a.s.

Terminated

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

Epithelial Ovarian Carcinoma

Germany, Poland, Czech Republic
University of Utah

Completed

Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand

Epithelial Ovarian Cancer

United States
Vanderbilt University
National Cancer Institute (NCI); Celgene Corporation

Completed

Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Ovarian Cancer

United States
AbbVie (prior sponsor, Abbott)
Biogen

Completed

Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

Ovarian Cancer, Primary Peritoneal Cancer

United States, Australia, Belgium, Italy, Poland, Russian Federation, Spain, Sweden, Switzerland
Assistance Publique - Hôpitaux de Paris

Terminated

Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma (ITOV04)

Ovarian Cancer | Relapses

France
Neovii Biotech

Completed

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Ovarian Cancer | Epithelial Ovarian Cancer

Austria, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
Johnson & Johnson Pharmaceutical Research & Development...
ALZA; Sequus Pharmaceuticals

Terminated

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Ovarian Neoplasms
AbbVie
Genentech, Inc.

Completed

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

Solid Tumors | Lymphoid Malignancy
Samuel Kim, MD

Completed

Human Ovarian Autotransplantation

Ovarian Autotransplantation Using Cryopreserved Ovarian Tissue in Women Treated for Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Adult Type Ovarian Granulosa Cell Tumor | Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor

United States, Japan
Assisting Nature

Unknown

Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.

Infertility | Premature Ovarian Failure

Greece
University of Palermo

Not yet recruiting

Experience in Borderline Ovarian Tumors

Borderline Ovarian Tumor
Zhongda Hospital

Not yet recruiting

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Ovarian Cancer, Epithelial

China
Peking Union Medical College Hospital
Zai Lab (Shanghai) Co., Ltd.

Not yet recruiting

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi (t)

Epithelial Ovarian Cancer

3

Subscribe